The standard of care (SOC) for COVID-19 evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. In this post hoc analysis of a series of… Click to show full abstract
The standard of care (SOC) for COVID-19 evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. In this post hoc analysis of a series of phase 3 trials that evaluated COVID-19 therapeutics from February 2020 through May 2021, the authors sought to evaluate whether recovery and mortality improved as the SOC evolved.
               
Click one of the above tabs to view related content.